Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147757 | 0.84 | MAOB (0.35) | GRIA1MAOBNPC1HTR2CCYP19A1 | |
| SCHEMBL3227142 | 0.81 | GRIA1 (0.60) | GRIA1MAOBNPC1HTR2CCYP19A1 | |
| SCHEMBL11928330 | 0.79 | GRIA1 (0.43) | GRIA1PIK3C3MTORHSD17B10 | |
| SCHEMBL13492426 | 0.75 | GRIA1 (0.40) | GRIA1NPC1KDM4EALDH1A1 | |
| SCHEMBL19166896 | 0.69 | GRIA1 (0.60) | GRIA1MAOBHTR2CCYP19A1HTR2A | |
| SCHEMBL20786546 | 0.68 | NPC1 (0.43) | MAOBNPC1HTR2CCYP19A1PRKDC | |
| SCHEMBL4067017 | 0.67 | CYP19A1 (0.41) | MAOBNPC1HTR2CCYP19A1HTR2A | |
| SCHEMBL13595240 | 0.66 | HTR2C (0.65) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4419505 | 0.65 | HTR2C (0.64) | HTR2CHTR2AHTR2B | |
| SCHEMBL16440168 | 0.65 | AAK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | GRIN1, GRIN3B, GABRE | GRIA1 26/4885MAOB 418/4885NPC1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.